uniQure N.V. (0EE0.L)
USD 16.7
(1.06%)
USD 16.7
(1.06%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -102.95 Million USD | -20.95% |
| 2022 | -85.12 Million USD | 79.76% |
| 2021 | -420.53 Million USD | -142.54% |
| 2020 | -173.38 Million USD | 43.1% |
| 2019 | -304.73 Million USD | -52.8% |
| 2018 | -199.42 Million USD | -43.27% |
| 2017 | -139.19 Million USD | -23.99% |
| 2016 | -112.26 Million USD | 44.24% |
| 2015 | -201.33 Million USD | -360.12% |
| 2014 | -43.75 Million USD | -101.58% |
| 2013 | -21.7 Million USD | -8877.44% |
| 2012 | 247.3 Thousand USD | 120.74% |
| 2011 | -1.19 Million USD | 94.92% |
| 2010 | -23.45 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -184.03 Million USD | -174.64% |
| 2024 Q2 | 246.56 Million USD | -17.66% |
| 2024 Q1 | 299.43 Million USD | 390.85% |
| 2023 Q2 | -374.51 Million USD | -3059.38% |
| 2023 FY | -102.95 Million USD | -20.95% |
| 2023 Q1 | -11.85 Million USD | 86.07% |
| 2023 Q4 | -102.95 Million USD | -12.9% |
| 2023 Q3 | -91.18 Million USD | 75.65% |
| 2022 Q1 | -389.47 Million USD | 7.38% |
| 2022 FY | -85.12 Million USD | 79.76% |
| 2022 Q4 | -85.12 Million USD | 71.78% |
| 2022 Q3 | -301.59 Million USD | 16.55% |
| 2022 Q2 | -361.4 Million USD | 7.21% |
| 2021 Q1 | -155.4 Million USD | 10.37% |
| 2021 Q3 | -471.44 Million USD | 17.33% |
| 2021 Q4 | -420.53 Million USD | 10.8% |
| 2021 FY | -420.53 Million USD | -142.54% |
| 2021 Q2 | -570.26 Million USD | -266.96% |
| 2020 Q2 | -243.11 Million USD | 9.76% |
| 2020 FY | -173.38 Million USD | 43.1% |
| 2020 Q1 | -269.4 Million USD | 11.59% |
| 2020 Q4 | -173.38 Million USD | 16.69% |
| 2020 Q3 | -208.11 Million USD | 14.4% |
| 2019 Q4 | -304.73 Million USD | 8.09% |
| 2019 Q3 | -331.55 Million USD | -195.54% |
| 2019 FY | -304.73 Million USD | -52.8% |
| 2019 Q1 | -146 Million USD | 26.79% |
| 2019 Q2 | -112.18 Million USD | 23.16% |
| 2018 Q4 | -199.42 Million USD | 8.87% |
| 2018 Q3 | -218.83 Million USD | 8.17% |
| 2018 Q2 | -238.31 Million USD | -98.58% |
| 2018 Q1 | -120 Million USD | 13.4% |
| 2018 FY | -199.42 Million USD | -43.27% |
| 2017 FY | -139.19 Million USD | -23.99% |
| 2017 Q3 | -68.34 Million USD | 18.26% |
| 2017 Q1 | -99.9 Million USD | 11.0% |
| 2017 Q4 | -138.58 Million USD | -102.75% |
| 2017 Q2 | -83.61 Million USD | 16.31% |
| 2016 Q3 | -136.24 Million USD | 16.47% |
| 2016 FY | -112.26 Million USD | 44.24% |
| 2016 Q2 | -163.12 Million USD | 13.35% |
| 2016 Q1 | -188.24 Million USD | 6.5% |
| 2016 Q4 | -112.26 Million USD | 17.61% |
| 2015 Q2 | -182.4 Million USD | -613.08% |
| 2015 FY | -201.33 Million USD | -360.12% |
| 2015 Q4 | -201.33 Million USD | 8.54% |
| 2015 Q3 | -220.13 Million USD | -20.68% |
| 2015 Q1 | -25.57 Million USD | 41.54% |
| 2014 Q4 | -43.75 Million USD | 25.64% |
| 2014 Q2 | -77.99 Million USD | 19.09% |
| 2014 Q3 | -58.84 Million USD | 24.55% |
| 2014 Q1 | -96.39 Million USD | -326.53% |
| 2014 FY | -43.75 Million USD | -101.58% |
| 2013 Q1 | 336.98 Thousand USD | 36.26% |
| 2013 Q2 | 19.08 Million USD | 5564.54% |
| 2013 Q4 | -22.59 Million USD | 28.8% |
| 2013 Q3 | -31.73 Million USD | -266.27% |
| 2013 FY | -21.7 Million USD | -8877.44% |
| 2012 Q4 | 247.3 Thousand USD | 0.0% |
| 2012 FY | 247.3 Thousand USD | 120.74% |
| 2011 FY | -1.19 Million USD | 94.92% |
| 2010 FY | -23.45 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Editas Medicine, Inc. | -87.11 Million USD | -18.177% |
| Dynavax Technologies Corporation | 106.63 Million USD | 196.545% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | -207.069% |
| Perrigo Company plc | 3.32 Billion USD | 103.099% |
| Illumina, Inc. | 1.21 Billion USD | 108.48% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 100.384% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 9.603% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 101.25% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 100.801% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 170.963% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | -279.893% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 1532.461% |
| Waters Corporation | 1.96 Billion USD | 105.251% |
| Biogen Inc. | 6.28 Billion USD | 101.637% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | -1350.014% |
| Evolus, Inc. | 63.7 Million USD | 261.598% |
| Adicet Bio, Inc. | -142 Million USD | 27.503% |
| Cara Therapeutics, Inc. | -9.01 Million USD | -1041.87% |
| bluebird bio, Inc. | 108.57 Million USD | 194.824% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 122.444% |
| FibroGen, Inc. | 56.76 Million USD | 281.357% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 108.991% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 1577.467% |
| Homology Medicines, Inc. | 18.43 Million USD | 658.393% |
| Geron Corporation | 14.76 Million USD | 797.453% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 106.494% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 151.978% |
| Myriad Genetics, Inc. | 88.1 Million USD | 216.857% |
| Viking Therapeutics, Inc. | -54.25 Million USD | -89.75% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 7.586% |
| Zoetis Inc. | 4.76 Billion USD | 102.162% |
| Abeona Therapeutics Inc. | -10.07 Million USD | -922.252% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 104.907% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 127.182% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 98.924% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | -606.499% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 109.765% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 422.882% |
| Verastem, Inc. | -37.27 Million USD | -176.171% |
| Nektar Therapeutics | 210.24 Million USD | 148.968% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 48.478% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | -179.728% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 110.631% |
| OPKO Health, Inc. | 230.68 Million USD | 144.629% |
| Exelixis, Inc. | -73.05 Million USD | -40.932% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 158.066% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 23.965% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 31.831% |
| Imunon, Inc. | -4.69 Million USD | -2090.786% |
| Blueprint Medicines Corporation | 702.83 Million USD | 114.648% |
| Insmed Incorporated | 721.62 Million USD | 114.267% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 107.455% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | -229.791% |
| TG Therapeutics, Inc. | 17.86 Million USD | 676.369% |
| Incyte Corporation | -3.17 Billion USD | 96.758% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 113.444% |